

## Alkaline Phosphatase (IFCC method)



### Order Information

Cat. No. OMR1014  
 Kit Configuration  
 Reagent 1: 2 x 40 mL  
 Reagent 2: 2 x 10 mL

### Summary


Alkaline Phosphatase (ALP) is hydrolytic enzyme acting ideally at alkaline pH, exists in blood in various different structures which originate from the most part from bone and liver, and also from different tissues such as kidney, placenta, testicles, thymus, lung and tumors. Physiological increments are found amid bone development in adolescence and in pregnancy, while pathological increments are to a great extent connected with hepatobiliary and bone diseases. In hepatobiliary disease they show hindrance of the bile conduits as in cholestasis brought about by gall stones, tumors or inflammation. Elevated activities of Alkaline Phosphatase are also observed in infectious hepatitis. In bone diseases elevated ALP activities start from increased osteoblastic activity as in Paget's disease, osteomalacia (rickets), bone metastases and hyperparathyroidism.

### Method

Kinetic photometric test, according to the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC).

### Principle

The increase in absorbance due to formation of 4-nitrophenolate is measured photometrically and is directly proportional to ALP activity in sample.



### Reagents Storage Instructions and Stability

Reagent are stable up to the end of the indicated month of expiry, if stored at 2 – 8°C, protected from light and contamination is avoided. Do not freeze the reagents!

Reagent 1: Buffer  
 Solution Reagent 2:  
 Substrate Solution

### Composition:

Reagent: 2-Amino methyl propanol 63 mL/L, Zinc sulphate 1 g/L, Magnesium acetate 1 g/L, p-Nitrophenylphosphate 10 g/L

### Warnings and Precautions

1. Do not swallow! Avoid contact with skin and mucous membranes.
2. In very rare cases, samples of patients with gammopathy might give falsified results.
3. N-acetyl cysteine (NAC), acetaminophen and metimazole medication leads to falsely low results in patient samples.
4. Please refer to the safety data sheets and take the necessary precautions for the use of laboratory reagents. For diagnostic purposes, the results should always be assessed with the patient's medical history, clinical examinations and other findings.
5. For professional use only!

### Waste Management

Please refer to local legal requirements.

### Reagent Preparation

For Working Reagent: Mix 4 parts of Reagent 1 + 1 part of Reagent 2.

(E.g. 20 mL R1 + 5 mL R2) = Working reagent  
 Stability: 4 weeks at 2 – 8 °C.

The Working reagent must be protected from light.

### Materials required but not provided

NaCl solution 9 g/L  
 General laboratory equipment

### Specimen

Serum, heparin plasma or EDTA plasma  
 Stability: 1 month at 2° – 8 °C, 3 months at -20 °C  
 Only freeze once!  
 Discard contaminated specimens.

### Assay Procedure

Application sheets for automated systems are available on request.

Wavelength 405nm (400-420 nm)  
 Optical path 1 cm  
 Temperature 37°C

### Sample start

|  | Sample  |
|--|---------|
| Sample   | 20 µL   |
| Working Reagent  | 1000 µL |
| Mix, Incubate for 1 min. and read absorbance after every 1 min. for 3 min. |         |

### Substrate start

|   | Sample/Calibrator |
|---|-------------------|
| Sample  | 20 µL             |
| Reagent 1   | 1000 µL           |
| Reagent 2   | 250 µL            |
| Mix, Incubate for 1 min. and read absorbance after every 1 min. |                   |

### Calculation

For activity, take  $\Delta A/\text{min}$  and multiply by the corresponding factor from table below:

ALP activity U/L =  $\Delta A/\text{min} \times \text{factor}$ .

### Factor

|                 |        |      |
|-----------------|--------|------|
| Sample start    | 405 nm | 2757 |
| Substrate start | 405 nm | 3433 |

### Conversion factor

ALP [U/L]  $\times 0.0167 =$  ALP [ $\mu\text{kat/L}$ ]

### Quality Controls

For internal quality control any normal and abnormal controls should be assayed with each batch of samples. Each laboratory should establish corrective action in case of deviations in control recovery.

### Performance Characteristics

#### Measuring range

The test has been developed to determine Alkaline Phosphatase activities within a measuring range from 3-1000

U/L. When values exceed this range samples should be diluted 1 + 4 with NaCl solution (9 g/L) and the result multiplied by 5.

#### Specificity/Interferences

No interference was observed by, Ascorbic Acid up to 30 mg/dL, Bilirubin up to 40 mg/dL and triglycerides up to 2000 mg/dL.

#### Sensitivity/Limit of Detection

The lower limit of detection is 3 U/L.

#### Linearity

The higher limit of detection is 1000 U/L.

#### Precision

| Intra-assay<br>n = 20 | Mean<br>[U/L] | SD<br>[U/L] | CV<br>[%] |
|-----------------------|---------------|-------------|-----------|
| Sample 1              | 267.06        | 4.63        | 1.74      |
| Sample 2              | 67.63         | 1.21        | 1.79      |

| Inter-assay n = 20 | Mean<br>[U/L] | SD<br>[U/L] | CV<br>[%] |
|--------------------|---------------|-------------|-----------|
| Sample 1           | 277.34        | 3.84        | 1.39      |
| Sample 2           | 68.40         | 1.02        | 1.49      |

### Method Comparison

A comparison of Nucleus Diagnosys Alkaline Phosphatase (y) with a commercially available test (x) using 15 samples gave following results:

$y = 0.998x + 0.128$ ;  $r^2 = 0.997$ .

### Literature

1. Thomas L. Clinical Laboratory Diagnostics. 1<sup>st</sup> ed. Frankfurt: TH-Books Verlagsgesellschaft; 1998. p.131-7.

### Reference Range

| Adults |              |                                   |
|--------|--------------|-----------------------------------|
| Women  | 35-104 (U/L) | 0.58 – 1.74 ( $\mu\text{kat/L}$ ) |
| Men    | 40-129 (U/L) | 0.67 – 2.15 ( $\mu\text{kat/L}$ ) |

|               | Male      |                       | Female    |                       |
|---------------|-----------|-----------------------|-----------|-----------------------|
|               | (U/L)     | ( $\mu\text{kat/L}$ ) | (U/L)     | ( $\mu\text{kat/L}$ ) |
| 1 – 30 days   | 75 – 316  | 1.25 – 5.27           | 48 – 406  | 0.80 – 6.77           |
| 30 – 365 days | 82 – 383  | 1.37 – 6.38           | 124 – 341 | 2.07 – 5.68           |
| 1 – 3 years   | 104 – 345 | 1.73 – 5.75           | 108 – 317 | 1.80 – 5.28           |
| 4 – 6 years   | 93 – 309  | 1.55 – 5.15           | 96 – 297  | 1.60 – 4.95           |
| 7 – 9 years   | 86 – 315  | 1.43 – 5.25           | 69 – 325  | 1.15 – 5.42           |
| 10 – 12 years | 42 – 362  | 0.70 – 6.03           | 51 – 332  | 0.85 – 5.53           |
| 13 – 15 years | 74 – 390  | 1.23 – 6.50           | 50 – 162  | 0.83 – 2.70           |
| 16-18 years   | 52 – 171  | 0.87 – 2.85           | 47 – 119  | 0.78 – 1.98           |

2. Deutsche Gesellschaft für klinische Chemie. Empfehlungen der deutschen Gesellschaft für Klinische Chemie (DGKC). Standardisierung von Methoden zur Bestimmung von Enzymaktivitäten in biologischen Flüssigkeiten. (Recommendation of the German Society of Clinical Chemistry. Standardization of methods for measurement of enzymatic activities in biological fluids.) Z Klin Chem Klin Biochem 1972; 10:182-92.
3. Guder WG, Zawta B et al. The Quality of Diagnostic Samples. 1<sup>st</sup> ed. Darmstadt: GIT Verlag; 2001; p. 14-5.
4. Young DS. Effects of Drugs on Clinical Laboratory Tests. 5th ed. Volume 1 and 2. Washington, DC: The American Association for Clinical Chemistry Press 2000.
5. Fischbach F, Zawta B. Age-dependent reference limits of several enzymes in plasma at different measuring temperatures. Klin Lab 1992; 38:555-61.
6. Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007; 45(9):1240-1243.

MANUFACTURED BY: NUCLEUS DIAGNOSYS LLP, INDIA

Marketed By: ORCHARD MEDICAL,

DIAMOND ARCADE, 68 JESSORE ROAD,

1<sup>st</sup> FLOOR, UNIT No. 110 & 112, KOLKATA – 700 055

CUSTOMER CARE No: 84200 69980

CUSTOMER CARE E-MAIL: sales.orchardmedical@gmail.com